FDA approves Xifaxan 550 mg

FDA approved an NDA from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) for Xifaxan rifaximin 550 mg tablets to reduce the risk of overt hepatic encephalopathy (HE) recurrence in patients with advanced live...